Condition
Autoimmune Encephalitis (AE) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Autoimmune Encephalitis (AE) clinical trials that are recruiting, at sites in 4 countries (most in China (2), France (1), Egypt (1)). By phase: Early Phase 1 (1), Phase 1 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 4Countries
Newest Autoimmune Encephalitis (AE) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Daily vs alternate-day plasma exchange in pediatric autoimmune encephalitis | — | Shibīn al Kawm, Menoufia Governorate | Recruiting | Jul 16, 2026 |
| OPM-MEG Brain Imaging in Young People with Immune- and Non-immune Related Neurological Disease | — | Birmingham, West Midlands and 1 other locations | Recruiting | Jul 8, 2026 |
| QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases | Phase 1 | Wuhan, Hubei | Recruiting | Apr 13, 2026 |
| [18F]-DPA-714 PET to detect brain inflammation in autoimmune encephalitis | Phase 2 | Toulouse | Recruiting | Mar 23, 2026 |
| CD19/BCMA-targeted UCAR-T for neurological autoimmune disorders | Early Phase 1 | Wuhan, Hubei | Recruiting | Jan 13, 2026 |
All recruiting trials (5)
-
Daily vs alternate-day plasma exchange in pediatric autoimmune encephalitis
This study tests whether giving plasma exchange on consecutive days is better than every other day for kids with autoimmune encephalitis.
-
OPM-MEG Brain Imaging in Young People with Immune- and Non-immune Related Neurological Disease
Researchers will test a fancy, child-friendly brain scan (OPM-MEG) to see how brain networks look in kids with autoimmune or other brain diseases and how that relates to their symptoms.
-
QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases
This Phase 1 test will see if QH103 (universal CD19 CAR-γδT) cell injections are safe and tolerated in adults with relapsed or treatment‑resistant antibody-mediated neurological diseases such as MS, NMOSD, AE, CIDP, or MG.
-
[18F]-DPA-714 PET to detect brain inflammation in autoimmune encephalitis
This test tries to see if [18F]-DPA-714 PET scans can detect brain inflammation in adults newly diagnosed with autoimmune encephalitis.
-
CD19/BCMA-targeted UCAR-T for neurological autoimmune disorders
This trial tests an off-the-shelf CD19/BCMA UCAR-T cell therapy with lymphodepletion in adults with relapsing or treatment-resistant MS, myasthenia gravis, CIDP, or autoimmune encephalitis.
Related topics
Quick answers
How many Autoimmune Encephalitis (AE) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in China (2 trials), France (1 trial), Egypt (1 trial), United Kingdom (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Early Phase 1: 1, Phase 1: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.